Pavlos Msaouel, MD, PhD, discusses the rationale for examining panitumumab-based treatment in SMARCB1-deficient RMC.
Pavlos Msaouel, MD, PhD
Advertisement
Articles by Pavlos Msaouel, MD, PhD
Pavlos Msaouel, MD, PhD, discusses how exercise can influence risk for patients with sickle cell trait to develop renal medullary carcinoma.
Pavlos Msaouel, MD, PhD, discusses the rationale for a phase II study evaluating sitravatinib in combination with nivolumab in patients with metastatic or advanced urothelial cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5